Orthofix and MTF Biologics Expand Partnership Agreement | national company

LEWISVILLE, Texas–(BUSINESS WIRE)–May 3, 2022–

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company specializing in spine and orthopedics, today announced the renewal and expansion of its partnership agreement with MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donations, serving patients and advancing science. The collaboration extends Orthofix’s exclusive commercialization rights to the Trinity™ allograft line through 2032 and includes an expansion agreement for the development of demineralized bone matrix (DBM) which Orthofix will market under the Legacy brand ™.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220503005524/en/

Legacy™ Demineralized Bone Matrix expands and complements the Orthofix range of biological solutions for spine and orthopedic surgical applications. (Photo: BusinessWire)

“Together, Orthofix and MTF Biologics have a long history of bringing advanced biological solutions to market, with more than 350,000 patients receiving their Trinity allografts,” said Kevin Kenny, President of Orthofix at Global Spine. “This agreement reinforces our partnership with MTF Biologics as a single-source provider of MTF allograft offerings. The addition of the Legacy Demineralized Bone line will expand our biologics portfolio, increasing the options available and providing a valuable solution for our customers and their patients.

“MTF Biologics is delighted to strengthen its exclusive partnership with Orthofix to continue our joint investments in innovative solutions and the delivery of Trinity Elite™ and Trinity Evolution™ allografts,” said Joe Yaccarino, President and CEO of MTF Biologics. . “This agreement aligns with MTF Biologics’ mission to honor donor families by serving patients who need innovative transplants and allograft solutions to help them on their path to recovery.”

The Legacy DBM will be a complimentary addition to the Orthofix demineralized bone line which consists of FiberFuse™ Advanced and FiberFuse Strip, both also supplied by MTF Biologics. A demineralized cortical bone powder with a sodium hyaluronate carrier, Legacy DBM will be applicable in spinal and orthopedic procedures. The parties plan to make the Legacy DBM available to customers starting in the third quarter of 2022.

Orthofix recognizes the important role of biological solutions in spine surgery and orthopedic applications. In addition to MTF Biologics Allograft Solutions, Orthofix proudly markets and distributes Opus™ Mg Set Bone Void Filler, Opus BA Bioactive Bone Graft, Collage™ Osteoconductive Scaffold, and O-Genesis™ Graft Delivery System. This broad portfolio gives surgeons the flexibility to select the best option to meet their procedural and patient needs.

About Orthofix

Orthofix Medical Inc. is a global medical device company specializing in spine and orthopedics. The company’s mission is to provide innovative, quality-driven solutions while partnering with healthcare professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic products are distributed in more than 60 countries through the company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.

About MTF Biologics

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donations, serving patients and advancing science. They offer unparalleled service, resources and expertise to donors and their loved ones who donate, people who depend on tissue and organ transplants, healthcare providers, clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a division of MTF Biologics, honors non-transplantable organ donors by offering their donations to the medical research community to fight and cure disease. Statline, also a division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue and eye procurement organizations, as well as the hospitals and patients they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (the German Institute for Cell and Tissue Transplantation), extends its reach to patients worldwide. For more information, visit www.mtfbiologics.org.

Forward-looking statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial prospects, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, ” estimates”, “projects”, “intends”, “predicts”, “potential” or “continues” or any other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our report. Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”). In addition to the risks described herein, factors that could cause or contribute to such differences may include, but are not limited to: the risk that surgeons may be slow to adopt Legacy DBM; the risk that future patient studies or clinical experience and data indicate that treatment with Trinity allografts or Legacy DBM may not improve patient outcomes as much as previously believed, or call into question the benefits the use of these products for patients, hospitals and surgeons; the risk that products may not perform as intended and therefore may not continue or achieve commercial success; the risk of competitors developing superior products or gaining a greater market position allowing for more successful commercialization; the risk that insurers refuse to reimburse healthcare providers for the use of our products.

This list of risks, uncertainties and other factors is not exhaustive. We discuss some of these matters, as well as certain risk factors that could affect our business, financial condition, results of operations and outlook, in more detail in our reports that we file from time to time with the SEC, which are available for reading at www.sec.gov. Any or all of the forward-looking statements we make may prove to be incorrect (due to inaccurate assumptions we make or otherwise), and our actual results and outcomes may differ materially from those expressed in such forward-looking statements. You should not place undue reliance on any of these forward-looking statements. In addition, any forward-looking statement speaks only as of the date hereof, unless specifically stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any obligation to update, our forward-looking statements, whether as a result of circumstances or events occurring after the date hereof, new information or otherwise.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220503005524/en/

CONTACT: Alexa Huerta

Investor Relations

Tel 214 937 3190

alexahuerta@orthofix.comDenise Landry

Media Relations

Tel 214 937 2529

deniselandry@orthofix.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: SCIENCE OTHER PHILANTHROPY OTHER SCIENTIFIC RESEARCH HEALTH MEDICAL DEVICES PHILANTHROPY OTHER HEALTH

SOURCE: Orthofix Medical Inc.

Copyright BusinessWire 2022.

PUBLISHED: 05/03/2022 07:00 AM/DISC: 05/03/2022 07:02 AM

http://www.businesswire.com/news/home/20220503005524/en

.

Leave a Reply

Your email address will not be published.